Glycoproteins Stocks List

Glycoproteins Stocks Recent News

Date Stock Title
Nov 1 ADMA ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle
Nov 1 ADMA ADMA Biologics jumps as KPMG becomes new auditor
Nov 1 ZYME Zymeworks Q4 2024 Earnings Preview
Nov 1 ZYME Zymeworks drops as Wells Fargo cuts on valuation
Nov 1 XNCR Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect?
Nov 1 ZYME Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year
Nov 1 ZYME Zymeworks Inc. 2024 Q3 - Results - Earnings Call Presentation
Nov 1 ZYME Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript
Oct 31 ZYME Zymeworks GAAP EPS of -$0.39 in-line, revenue of $16M misses by $1.85M
Oct 31 ZYME Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Oct 31 EQ Equillium says Ono not acquiring itolizumab, stock craters 36%
Oct 31 EQ Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
Oct 31 EQ Equillium Maintains Rights to Itolizumab Following Ono Partnership
Oct 31 SABS SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
Oct 31 EQ Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Oct 30 ZYME Zymeworks Q3 2024 Earnings Preview
Oct 30 XNCR Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
Oct 29 ADMA Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Oct 29 ADMA ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
Oct 29 XNCR Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy?
Glycoproteins

Glycoproteins are proteins which contain oligosaccharide chains (glycans) covalently attached to amino acid side-chains. The carbohydrate is attached to the protein in a cotranslational or posttranslational modification. This process is known as glycosylation. Secreted extracellular proteins are often glycosylated.
In proteins that have segments extending extracellularly, the extracellular segments are also often glycosylated. Glycoproteins are also often important integral membrane proteins, where they play a role in cell–cell interactions. It is important to distinguish endoplasmic reticulum-based glycosylation of the secretory system from reversible cytosolic-nuclear glycosylation. Glycoproteins of the cytosol and nucleus can be modified through the reversible addition of a single GlcNAc residue that is considered reciprocal to phosphorylation and the functions of these are likely to be additional regulatory mechanism that controls phosphorylation-based signalling. In contrast, classical secretory glycosylation can be structurally essential. For example, inhibition of asparagine-linked, i.e. N-linked, glycosylation can prevent proper glycoprotein folding and full inhibition can be toxic to an individual cell. In contrast, perturbation of glycan processing (enzymatic removal/addition of carbohydrate residues to the glycan), which occurs in both the endoplastic reticulum and Golgi apparatus, is dispensable for isolated cells (as evidence by survival with glycosides inhibitors) but can lead to human disease (congenital disorders of glycosylation) and can be lethal in animal models. It is therefore likely that the fine processing of glycans is important for endogenous functionality, such as cell trafficking, but that this is likely to have been secondary to its role in host-pathogen interactions. A famous example of this latter effect is the ABO blood group system.

Browse All Tags